Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NBIX's Cash to Debt is ranked higher than
98% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. NBIX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NBIX' s Cash to Debt Range Over the Past 10 Years
Min: 1.72  Med: 39.45 Max: No Debt
Current: No Debt
Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
96% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. NBIX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBIX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 46.25
M-Score: 20.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -424.51
NBIX's Operating margin (%) is ranked lower than
94% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. NBIX: -424.51 )
Ranked among companies with meaningful Operating margin (%) only.
NBIX' s Operating margin (%) Range Over the Past 10 Years
Min: -17340.03  Med: -288.82 Max: 43.82
Current: -424.51
-17340.03
43.82
Net-margin (%) -399.91
NBIX's Net-margin (%) is ranked lower than
94% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. NBIX: -399.91 )
Ranked among companies with meaningful Net-margin (%) only.
NBIX' s Net-margin (%) Range Over the Past 10 Years
Min: -16936.19  Med: -273.25 Max: 48.53
Current: -399.91
-16936.19
48.53
ROE (%) -21.58
NBIX's ROE (%) is ranked lower than
81% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NBIX: -21.58 )
Ranked among companies with meaningful ROE (%) only.
NBIX' s ROE (%) Range Over the Past 10 Years
Min: -250.63  Med: -35.17 Max: 94.61
Current: -21.58
-250.63
94.61
ROA (%) -19.45
NBIX's ROA (%) is ranked lower than
83% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. NBIX: -19.45 )
Ranked among companies with meaningful ROA (%) only.
NBIX' s ROA (%) Range Over the Past 10 Years
Min: -62.22  Med: -25.43 Max: 26.57
Current: -19.45
-62.22
26.57
ROC (Joel Greenblatt) (%) -1280.20
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. NBIX: -1280.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBIX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3011.27  Med: -215.22 Max: 2175.88
Current: -1280.2
-3011.27
2175.88
Revenue Growth (3Y)(%) -100.00
NBIX's Revenue Growth (3Y)(%) is ranked lower than
99% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NBIX: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBIX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -100  Med: -10.80 Max: 175.9
Current: -100
-100
175.9
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

NBIX Guru Trades in Q4 2014

Pioneer Investments 238,621 sh (-52.65%)
» More
Q1 2015

NBIX Guru Trades in Q1 2015

RS Investment Management 596,880 sh (New)
Steven Cohen 233,200 sh (New)
Paul Tudor Jones 6,635 sh (New)
Pioneer Investments 193,871 sh (-18.75%)
» More
Q2 2015

NBIX Guru Trades in Q2 2015

Louis Moore Bacon 55,000 sh (New)
RS Investment Management 711,010 sh (+19.12%)
RS Investment Management 711,010 sh (+19.12%)
Paul Tudor Jones Sold Out
Pioneer Investments 144,315 sh (-25.56%)
Steven Cohen 37,700 sh (-83.83%)
» More
Q3 2015

NBIX Guru Trades in Q3 2015

Jim Simons 130,641 sh (New)
RS Investment Management 838,960 sh (+18.00%)
Steven Cohen Sold Out
Pioneer Investments 116,672 sh (-19.15%)
Louis Moore Bacon 35,000 sh (-36.36%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Neurocrine Biosciences Inc

Meridian Funds Comments on Neurocrine Biosciences - Aug 31, 2015

Neurocrine Biosciences (NASDAQ:NBIX) is a pharmaceutical company with two development-stage programs focused on neurological and endocrine-based health problems. The company came to our attention after poor clinical trial results for one of its programs resulted in a 40% reduction in the share price. We invested because the issues with the trial were related to trial design, not drug efficacy. Management presented a credible plan for addressing the design issues, and the company’s valuation was capturing only a fraction of the potential cash flows that could be generated by both drug programs. Over the past year, both of Neurocrine’s drug programs have delivered strong clinical trial results and are on track for commercialization, which may drive significant earnings and cash flow growth. We have reduced our position somewhat over the past year due to the strong appreciation in share price but continue to hold shares in Neurocrine Biosciences.



From Meridian Growth Fund’s annual letter.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Neurocrine Biosciences Inc

Meridian Funds Comments on Neurocrine Biosciences Guru stock highlight
Neurocrine Biosciences (NASDAQ:NBIX) is a pharmaceutical company with two development-stage programs focused on neurological and endocrine-based health problems. The company came to our attention after poor clinical trial results for one of its programs resulted in a 40% reduction in the share price. We invested because the issues with the trial were related to trial design, not drug efficacy. Management presented a credible plan for addressing the design issues, and the company’s valuation was capturing only a fraction of the potential cash flows that could be generated by both drug programs. Over the past year, both of Neurocrine’s drug programs have delivered strong clinical trial results and are on track for commercialization, which may drive significant earnings and cash flow growth. We have reduced our position somewhat over the past year due to the strong appreciation in share price but continue to hold shares in Neurocrine Biosciences. Read more...

Ratios

vs
industry
vs
history
P/B 6.17
NBIX's P/B is ranked lower than
85% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. NBIX: 6.17 )
Ranked among companies with meaningful P/B only.
NBIX' s P/B Range Over the Past 10 Years
Min: 0.9  Med: 5.45 Max: 108
Current: 6.17
0.9
108
P/S 128.24
NBIX's P/S is ranked lower than
99% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. NBIX: 128.24 )
Ranked among companies with meaningful P/S only.
NBIX' s P/S Range Over the Past 10 Years
Min: 3.15  Med: 29.55 Max: 3940
Current: 128.24
3.15
3940
Current Ratio 19.31
NBIX's Current Ratio is ranked higher than
96% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. NBIX: 19.31 )
Ranked among companies with meaningful Current Ratio only.
NBIX' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.49 Max: 26.66
Current: 19.31
1.63
26.66
Quick Ratio 19.31
NBIX's Quick Ratio is ranked higher than
96% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. NBIX: 19.31 )
Ranked among companies with meaningful Quick Ratio only.
NBIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.49 Max: 26.66
Current: 19.31
1.63
26.66

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.33
NBIX's Price/Net Cash is ranked higher than
53% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. NBIX: 9.33 )
Ranked among companies with meaningful Price/Net Cash only.
NBIX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.62  Med: 8.82 Max: 254.67
Current: 9.33
2.62
254.67
Price/Net Current Asset Value 9.15
NBIX's Price/Net Current Asset Value is ranked lower than
62% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NBIX: 9.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NBIX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.79  Med: 6.53 Max: 280
Current: 9.15
1.79
280
Price/Tangible Book 6.92
NBIX's Price/Tangible Book is ranked lower than
77% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. NBIX: 6.92 )
Ranked among companies with meaningful Price/Tangible Book only.
NBIX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 4.67 Max: 101.67
Current: 6.92
1.11
101.67
Price/Projected FCF 13.28
NBIX's Price/Projected FCF is ranked lower than
87% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. NBIX: 13.28 )
Ranked among companies with meaningful Price/Projected FCF only.
NBIX' s Price/Projected FCF Range Over the Past 10 Years
Min: 9.63  Med: 23.62 Max: 93.08
Current: 13.28
9.63
93.08
Price/Median PS Value 4.88
NBIX's Price/Median PS Value is ranked lower than
95% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. NBIX: 4.88 )
Ranked among companies with meaningful Price/Median PS Value only.
NBIX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.68 Max: 54.03
Current: 4.88
0.13
54.03
Earnings Yield (Greenblatt) (%) -3.54
NBIX's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. NBIX: -3.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NBIX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 8.60 Max: 3530
Current: -3.54
0.2
3530

More Statistics

Revenue(Mil) $22
EPS $ -0.95
Beta-0.04
Short Percentage of Float7.61%
52-Week Range $32.06 - 58.46
Shares Outstanding(Mil)86.20

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 27 13 132 221
EPS($) -0.94 -1.87 -0.61 0.29
EPS without NRI($) -0.94 -1.87 -0.61 0.29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany,
Neurocrine Biosciences Inc, a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address pharmaceutical markets internationally, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company's two late-stage clinical programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II clinical studies of uterine fibroids that is partnered with AbbVie, and a wholly owned VMAT2 inhibitor for the treatment of movement disorders that is currently in Phase II development. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 

More From Other Websites
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 05 2016
Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 03 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in... Feb 02 2016
Stock Watchout on Drugs - Generic -- Mylan, Neurocrine Biosciences, Horizon Pharma, and Zoetis Feb 02 2016
AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine... Jan 28 2016
Four Stocks Driving Thursday’s Market Gains: How Did They Do It? Jan 14 2016
Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 5, 2016 Jan 05 2016
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
4 stocks to watch Dec 31 2015
5 Top Performing Stocks of the Top ETF of 2015 Dec 28 2015
Niche Hedge Funds lead the pack in 2015 Dec 22 2015
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : December 22,... Dec 22 2015
NBIX: Successful Phase 1b Trial Results for NBI-98854 in Tourette Syndrome Caps a Banner Year for... Dec 18 2015
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in... Dec 16 2015
NEUROCRINE BIOSCIENCES INC Financials Dec 08 2015
Icahn School Of Medicine At Mount Sanai Files Complaint Against Neurocrine Sciences For Breach Of... Dec 02 2015
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events Dec 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK